Further Thoughts re Trillium Therapeutics

Trillium stock price was a roller coaster for years peeking on Apr 9, 2015 at $29.09 and bottoming out at $0.27 on Nov 12, 2019 around the time when new CEO Jan Skvarka joined the team. within a year the stock was trading at $20. It declined and the rebounded until the buyout by Pfizer.

RVX is trading at $0.07 on a sustained basis and ZCC, while it has many trials, the trials are proceeding slowly. Also, ZCC lacks liquidity. Both of these companies require new CEOs that can bring leadership and the requisite skill sets to allow these companies to move forward.

In the case of ZCC it may be a matter of promoting Dr Lakhotia to CEO and the giving him the resources to build his team and accelerate the pace of these exciting and promising trials.

In the case of RVX the CEO must be replaced by an outside biotech expert with strong financing, leadership and team building skills. With the exception of independent scientific papers being published RVX has been dormant since the failure of BoM.

Neither Eversana nor Cencora are solutions for the CEO problem. Both of these companies will benefit significantly with the leadership of a leading biotech CEO.

Just a POV.

GLTA

Toinv